Jay Daniels

Jay Daniels

Auto-generated profile, based on publicly available information

Jay Daniels

Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2017 in Blood
Verified
Journal Article
Closed access
PDF file
JPJoonhee Park
Joonhee Park
JYJingyi Yang
Jingyi Yang
AWAlexander T. Wenzel
Alexander T. Wenzel
ARAkshaya Ramachandran
Akshaya Ramachandran
WLWung J. Lee
Wung J. Lee
JCJaehyuk Choi
Jaehyuk Choi
Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell. In early-stage disease, lesions are limited to the skin, but in later-stage disease, the tumor cells can escape into the blood, the lymph nodes, and at times the visceral organs. To clarify the genomic basis of CTCL, we performed genomic analysis of 220 CTCLs. Our analyses identify 55 putative driver genes, including 17 genes not previously implicated in CTCL. These novel mutations are predicted to affect chromatin (BCOR, KDM6A, SMARCB1, TRRAP), immune surveillance (CD58, RFXAP), MAPK signaling (MAP2K1, NF1), NF-κB signaling (PRKCB, CSNK1A1), PI-3-kinase signaling (PIK3R1, VAV1), RHOA/cytoskeleton remodeling (ARHGEF3), RNA splicing (U2AF1), T-cell receptor signaling (PTPRN2, RLTPR), and T-cell differentiation (RARA). Our analyses identify recurrent mutations in 4 genes not previously identified in cancer. These include CK1α (encoded by CSNK1A1) (p.S27F; p.S27C), PTPRN2 (p.G526E), RARA (p.G303S), and RLTPR (p.Q575E). Last, we functionally validate CSNK1A1 and RLTPR as putative oncogenes. RLTPR encodes a recently described scaffolding protein in the T-cell receptor signaling pathway. We show that RLTPR (p.Q575E) increases binding of RLTPR to downstream components of the NF-κB signaling pathway, selectively upregulates the NF-κB pathway in activated T cells, and ultimately augments T-cell-receptor-dependent production of interleukin 2 by 34-fold. Collectively, our analysis provides novel insights into CTCL pathogenesis and elucidates the landscape of potentially targetable gene mutations. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Genomic analysis of 220 CTCLs identifies 55 genes in lymphomagenesis, including 17 genes not previously implicated in CTCL. RLTPR (p.Q575E) is a novel gain-of-function mutation that potentiates T-cell receptor signaling via selective upregulation of the NF-κB pathway.

5 May 2017 in Science
Verified
Journal Article
Closed access
PDF file
QLQili Liu
Qili Liu
MTMasashi Tabuchi
Masashi Tabuchi
SLSha Liu
Sha Liu
LKLay Kodama
Lay Kodama
WHWakako Horiuchi
Wakako Horiuchi
MWMark N. Wu
Mark N. Wu
The drive to eat protein is mediated by plastic changes in a dedicated neuronal circuit in Drosophila .

7 October 2021 in Blood
Verified
Journal Article
Open access
PDF file
JPJoonhee Park
Joonhee Park
JDJay Daniels
Jay Daniels
TWTim Wartewig
Tim Wartewig
KRKimberly G. Ringbloom
Kimberly G. Ringbloom
MMMaria Estela Martinez-Escala
Maria Estela Martinez-Escala
JCJaehyuk Choi
Jaehyuk Choi
Cutaneous T-cell lymphomas (CTCLs) are a clinically heterogeneous collection of lymphomas of the skin-homing T cell. To identify molecular drivers of disease phenotypes, we assembled representative samples of CTCLs from patients with diverse disease subtypes and stages. Via DNA/RNA-sequencing, immunophenotyping, and ex vivo functional assays, we identified the landscape of putative driver genes, elucidated genetic relationships between CTCLs across disease stages, and inferred molecular subtypes in patients with stage-matched leukemic disease. Collectively, our analysis identified 86 putative driver genes, including 19 genes not previously implicated in this disease. Two mutations have never been described in any cancer. Functionally, multiple mutations augment T-cell receptor–dependent proliferation, highlighting the importance of this pathway in lymphomagenesis. To identify putative genetic causes of disease heterogeneity, we examined the distribution of driver genes across clinical cohorts. There are broad similarities across disease stages. Many driver genes are shared by mycosis fungoides (MF) and Sezary syndrome (SS). However, there are significantly more structural variants in leukemic disease, leading to highly recurrent deletions of putative tumor suppressors that are uncommon in early-stage skin-centered MF. For example, TP53 is deleted in 7% and 87% of MF and SS, respectively. In both human and mouse samples, PD1 mutations drive aggressive behavior. PD1 wild-type lymphomas show features of T-cell exhaustion. PD1 deletions are sufficient to reverse the exhaustion phenotype, promote a FOXM1-driven transcriptional signature, and predict significantly worse survival. Collectively, our findings clarify CTCL genetics and provide novel insights into pathways that drive diverse disease phenotypes.

7 February 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JGJulie Garcia
Julie Garcia
JDJay Daniels
Jay Daniels
YLYujin Lee
Yujin Lee
IZIowis Zhu
Iowis Zhu
KCKathleen Cheng
Kathleen Cheng
JCJaehyuk Choi
Jaehyuk Choi

14 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JDJay Daniels
Jay Daniels
PDPeter G. Doukas
Peter G. Doukas
MEMaria E. Martinez Escala
Maria E. Martinez Escala
KRKimberly G. Ringbloom
Kimberly G. Ringbloom
DSDavid J. H. Shih
David J. H. Shih
JCJaehyuk Choi
Jaehyuk Choi
Primary cutaneous γδ T cell lymphomas (PCGDTLs) represent a heterogeneous group of uncommon but aggressive cancers. Herein, we perform genome-wide DNA, RNA, and T cell receptor (TCR) sequencing on 29 cutaneous γδ lymphomas. We find that PCGDTLs are not uniformly derived from Vδ2 cells. Instead, the cell-of-origin depends on the tissue compartment from which the lymphomas are derived. Lymphomas arising from the outer layer of skin are derived from Vδ1 cells, the predominant γδ cell in the epidermis and dermis. In contrast, panniculitic lymphomas arise from Vδ2 cells, the predominant γδ T cell in the fat. We also show that TCR chain usage is non-random, suggesting common antigens for Vδ1 and Vδ2 lymphomas respectively. In addition, Vδ1 and Vδ2 PCGDTLs harbor similar genomic landscapes with potentially targetable oncogenic mutations in the JAK/STAT, MAPK, MYC, and chromatin modification pathways. Collectively, these findings suggest a paradigm for classifying, staging, and treating these diseases.

18 September 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
TWTim Wartewig
Tim Wartewig
JDJay Daniels
Jay Daniels
MSMiriam Schulz
Miriam Schulz
EHErik Hameister
Erik Hameister
AJAbhinav Joshi
Abhinav Joshi
JRJürgen Ruland
Jürgen Ruland
The PDCD1-encoded immune checkpoint receptor PD-1 is a key tumor suppressor in T cells that is recurrently inactivated in T cell non-Hodgkin lymphomas (T-NHLs). The highest frequencies of PDCD1 deletions are detected in advanced disease, predicting inferior prognosis. However, the tumor-suppressive mechanisms of PD-1 signaling remain unknown. Here, using tractable mouse models for T-NHL and primary patient samples, we demonstrate that PD-1 signaling suppresses T cell malignancy by restricting glycolytic energy and acetyl coenzyme A (CoA) production. In addition, PD-1 inactivation enforces ATP citrate lyase (ACLY) activity, which generates extramitochondrial acetyl-CoA for histone acetylation to enable hyperactivity of activating protein 1 (AP-1) transcription factors. Conversely, pharmacological ACLY inhibition impedes aberrant AP-1 signaling in PD-1-deficient T-NHLs and is toxic to these cancers. Our data uncover genotype-specific vulnerabilities in PDCD1-mutated T-NHL and identify PD-1 as regulator of AP-1 activity.